Loading
A phase 1 trial of CBX-663 run by Crossbow Therapeutics, Inc., now recruiting.
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma. is a phase 1 interventional study registered as NCT07779798 by Crossbow Therapeutics, Inc., with 120 participants planned, started 2026-08-04. Conditions recorded: Advanced Solid Tumors, Recurrent or Progressive Glioblastoma and Relapse or Refractory Myeloid Malignancies. Interventions recorded: CBX-663.
Shares Glioma & glioblastoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Crossbow Therapeutics and the tag pipeline.
Shares Crossbow Therapeutics and the tag pipeline.
Shares Leukaemia (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Glioma & glioblastoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Glioma & glioblastoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Leukaemia (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/